Skip to main content
. 2018 Jan 8;9(6):6924–6937. doi: 10.18632/oncotarget.24023

Figure 4.

Figure 4

(A) MCF-7 breast cancer cells were treated with increasing doses of ZB716 or fulvestrant for 5 days. At the end of treatment, surviving cells were counted and normalized to control cells that were treated with vehicle (DMSO) only. (B) IC50 values were obtained by deriving logarithmic curves from the %cell survival vs. treatment dose plot.